Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07749157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

Study acronym: NOVA-BEAM
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 2 changed
See other at-risk trials from Roche/Genentech

Record History

  1. Primary endpoint(s) modified Eligibility criteria expanded, about 19 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 19 words
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
Trial Details
NCT Number NCT07749157
Lead Sponsor Hoffmann-La Roche
Conditions Relapsing Multiple Sclerosis
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov